Treatment-resistant Hypertension Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics

The Treatment-resistant Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Treatment-resistant Hypertension pipeline products will significantly revolutionize the Treatment-resistant Hypertension market dynamics.

DelveInsight's "Treatment-resistant Hypertension Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Treatment-resistant Hypertension, historical and forecasted epidemiology as well as the Treatment-resistant Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Treatment-resistant Hypertension market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Treatment-resistant Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Treatment-resistant Hypertension Market Forecast
https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Treatment-resistant Hypertension Market Report:
• The Treatment-resistant Hypertension market size was approximately USD 13 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, In its Q1 presentation, the company announced its intention to release topline results from the KARDIA-3 study and begin a Phase III cardiovascular outcomes trial for zilebesiran in the latter half of 2025.
• In its Q1 2025 presentation, Regeneron Pharmaceuticals revealed the launch of a Phase II clinical trial to assess REGN5381 as a treatment for uncontrolled hypertension.
• In March 2025, Idorsia Pharmaceuticals announced that the US FDA has officially removed the REMS (Risk Evaluation and Mitigation Strategy) requirement for TRYVIO. Additionally, the company is no longer obligated to carry out the post-marketing requirement (PMR) involving a global descriptive study gathering prospective and retrospective data on women exposed to TRYVIO during pregnancy and/or breastfeeding, as this information is no longer deemed necessary.
• In February 2025, Idorsia Pharmaceuticals stated that the exclusivity agreement made in November 2024 with an unnamed party for the global rights to aprocitentan has ended, as the party did not proceed with finalizing the deal outlined in the nonbinding term sheet.
• Germany held the largest market share for Treatment-Resistant Hypertension among the EU4 and the UK, accounting for around 6%
• Several prominent companies in the Treatment-Resistant Hypertension market, including Ionis Pharmaceutical's IONIS-AGT-LRx, KBP Biosciences' ocedurenone (KBP-5074), and others, are anticipated to influence the market dynamics from 2024 to 2034.
• According to DelveInsight's analysis, in 2023, there were around 16 million prevalent cases of Treatment-Resistant Hypertension across the 7MM, with nearly 10 million cases in the US. The prevalence is anticipated to rise during the forecast period, primarily driven by the increasing global obesity rates, a key risk factor for hypertension.
• Among the EU4 and the UK, Germany had the highest prevalence of Treatment-Resistant Hypertension, with around 1 million cases, followed by Italy with approximately 960 thousand cases and Spain with nearly 780 thousand cases.
• Resistant hypertension is more prevalent in females than males. In 2023, the US had around 5 million female cases compared to 4 million male cases.
• According to our estimates, in 2023, around 1 million cases were reported in individuals aged 20-49, with prevalence increasing with age, reaching approximately 4 million cases in those aged 70 and above.
• In 2023, Japan had the highest number of treatment-resistant hypertension cases, totaling nearly 2 million, with approximately 1 million cases in females and around 860 thousand in males.
• Key Treatment-resistant Hypertension Companies: Idorsia Pharmaceuticals, Ionis Pharmaceuticals, KBP Biosciences, Quantum Genomics, CinCor Pharma, Idorsia Ltd., Janssen Biotech, and others
• Key Treatment-resistant Hypertension Therapies: TRYVIOTM (Aprocitentan), IONIS-AGT-LRx, Ocedurenone (KBP-5074), Firibastat, CIN-107, Aprocitentan, and others
• The Treatment-resistant Hypertension epidemiology based on gender analyzed that RHTN is more prevalent in females as compared to males

Treatment-resistant Hypertension Overview
Treatment-resistant hypertension is high blood pressure that remains uncontrolled despite using three or more antihypertensive medications, including a diuretic, at optimal doses. It increases the risk of heart disease, stroke, and kidney failure. Causes may include obesity, sleep apnea, high salt intake, or secondary conditions requiring specialized treatments like renal denervation.

Get a Free sample for the Treatment-resistant Hypertension Market Report
https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Treatment-resistant Hypertension Market
The dynamics of the Treatment-resistant Hypertension market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"According to the first comprehensive global analysis of trends in hypertension prevalence, detection, treatment, and control, led by Imperial College London and WHO, the number of adults aged 30-79 years with hypertension has increased from 650 million to 1.28 billion in the last thirty years."

Treatment-resistant Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Treatment-resistant Hypertension Epidemiology Segmentation:
The Treatment-resistant Hypertension market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Treatment-resistant Hypertension
• Prevalent Cases of Treatment-resistant Hypertension by severity
• Gender-specific Prevalence of Treatment-resistant Hypertension
• Diagnosed Cases of Episodic and Chronic Treatment-resistant Hypertension

Download the report to understand which factors are driving Treatment-resistant Hypertension epidemiology trends @ Treatment-resistant Hypertension Epidemiological Insights
https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Treatment-resistant Hypertension Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Treatment-resistant Hypertension market or expected to get launched during the study period. The analysis covers Treatment-resistant Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Treatment-resistant Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Treatment-resistant Hypertension Therapies and Key Companies
• TRYVIOTM (Aprocitentan): Idorsia Pharmaceuticals
• IONIS-AGT-LRx: Ionis Pharmaceuticals
• Ocedurenone (KBP-5074): KBP Biosciences
• Firibastat: Quantum Genomics
• CIN-107: CinCor Pharma
• Aprocitentan: Idorsia Ltd / Janssen Biotech

To know more about Treatment-resistant Hypertension treatment, visit @ Treatment-resistant Hypertension Medications
https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Treatment-resistant Hypertension Market Strengths
• Expected launch of first-in-class drugs with novel MoA like aprocitentan, CIN-107 is likely to booth Treatment-resistant Hypertension market growth
• A robust pipeline of drugs with MoA different from SoC (single-pill three-drug combination) like firibastat (BAPAI molecule) is expected to offer RHTN patients alternative therapy options who are intolerant or contraindication to spironolactone

Treatment-resistant Hypertension Market Opportunities
• Spironolactone, despite being the first-choice drug as an add-on treatment option (PATHWAY-2 study) for Treatment-resistant Hypertension patients, there exists an urgent unmet need for alternative treatment options with better side-effect profile, novel MoA, ease of administration, etc.

Scope of the Treatment-resistant Hypertension Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Treatment-resistant Hypertension Companies: Idorsia Pharmaceuticals, Ionis Pharmaceuticals, KBP Biosciences, Quantum Genomics, CinCor Pharma, Idorsia Ltd., Janssen Biotech, and others
• Key Treatment-resistant Hypertension Therapies: TRYVIOTM (Aprocitentan), IONIS-AGT-LRx, Ocedurenone (KBP-5074), Firibastat, CIN-107, Aprocitentan, and others
• Treatment-resistant Hypertension Therapeutic Assessment: Treatment-resistant Hypertension current marketed and Treatment-resistant Hypertension emerging therapies
• Treatment-resistant Hypertension Market Dynamics: Treatment-resistant Hypertension market drivers and Treatment-resistant Hypertension market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Treatment-resistant Hypertension Unmet Needs, KOL's views, Analyst's views, Treatment-resistant Hypertension Market Access and Reimbursement

Discover more about therapies set to grab major Treatment-resistant Hypertension market share @ Treatment-resistant Hypertension Treatment Landscape
https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Treatment-resistant Hypertension Market Report Introduction
2. Executive Summary for Treatment-resistant Hypertension
3. SWOT analysis of Treatment-resistant Hypertension
4. Treatment-resistant Hypertension Patient Share (%) Overview at a Glance
5. Treatment-resistant Hypertension Market Overview at a Glance
6. Treatment-resistant Hypertension Disease Background and Overview
7. Treatment-resistant Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Treatment-resistant Hypertension
9. Treatment-resistant Hypertension Current Treatment and Medical Practices
10. Treatment-resistant Hypertension Unmet Needs
11. Treatment-resistant Hypertension Emerging Therapies
12. Treatment-resistant Hypertension Market Outlook
13. Country-Wise Treatment-resistant Hypertension Market Analysis (2020-2034)
14. Treatment-resistant Hypertension Market Access and Reimbursement of Therapies
15. Treatment-resistant Hypertension Market Drivers
16. Treatment-resistant Hypertension Market Barriers
17. Treatment-resistant Hypertension Appendix
18. Treatment-resistant Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Treatment-resistant Hypertension Epidemiology https://www.delveinsight.com/report-store/resistant-hypertension-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Treatment-resistant Hypertension Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Treatment-resistant Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market
• Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.